Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Drought is over, turn around day

<< Previous

Bullboard Posts

Next >>

Comment by stayhumble1on Apr 20, 2021 8:40pm

188 Views

Post# 33034400

RE:RE:RE:RE:Drought is over, turn around day

Canadafan, you say "the Bracelet results are 6-12 months away (some prelim results as early as 6 months). What is your source or reference for that time frame?

The information provided on the NIH Clinical Trials website in the Study Design section (last updated Mar30/2021) states the Bracelet Primary Completion Date is May 2021 and the Estimated Study Completion Date is June 2021... https://clinicaltrials.gov/ct2/show/NCT04215146?term=oncolytics+biotech&draw=2&rank=3

Anyone else care to weigh in on the Bracelt trial timeline? Has the company provided any recent guidance?

<< Previous

Bullboard Posts

Next >>

This battery metals stock is on a path to the global stage